Adcetris - Brentuximab Vedotin

Brentuximab vedotin (brand name: Adcetris) is a treatment for post-transplant consolidation, relapsed or refractory Hodgkin lymphoma (cancer of the lymphatic system distinguished by the presence of CD30-positive Reed-Sternberg cells), and systemic anaplastic large cell lymphoma (a type of aggressive T-cell lymphoma).